PubMed Health⌕ Search

Biomedical subjects

M Mairesse

Publications and source records attributed to M Mairesse.

34 records · Page 2Linked to original sources
PubMed1990

[Hyalinizing granuloma of the lung].

The authors report a case of a 44 year old patient with bilateral nodular lesions with a slow but progressive evolution and associated with a non-specific clinical picture. A thoracotomy enabled the diagnosis of a hyalinising granuloma of the lung to be made. Subsequently the appearance of a new lesion, and the risks of mediastinal extension suggested the use of corticotherapy and this rapidly led to a normalisation of the clinical and biological picture; as regards the radiology a partial regression of the nodular lesions was noted, and after 36 months of treatment there were no new lesions.

Adult↗
PubMed1990

[Endobronchial lipoma: a potential CT diagnosis].

Bronchial lipomas are rare and benign neoplasms. Computed tomography can provide a powerful adjunct to conventional modalities in determining the nature of an endobronchial lesion. The reflex vasoconstriction can also be nicely depicted.

Bronchial Neoplasms↗
PubMed1986

[Polychemotherapy of undifferentiated small cell bronchial cancer. Long-term results].

Long-term results of 2 studies combining etoposide and adriamycin with cisplatin (CAV) or cyclophosphamide (AVE) in small cell lung cancer indicate a 2-year survival rate of 22% and 18% respectively. The complete response rate 2 years after the onset of chemotherapy was 8% (8/98) : 11% (4/36) with CAV and 5% (4/62) with AVE. Among these 8 patients, 2 had a late relapse and one died of an unrelated cause. The actual long-term survival rate was 6% with CAV and 5% with AVE.

Adult↗
PubMed1986

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.

We conducted a randomized trial comparing a high (120 mg/m2 day 1) v a standard (60 mg/m2 day 1) dose of cisplatin in combination with etoposide (120 mg/m2 days 3, 5, and 7) in advanced non-small-cell lung carcinoma (NSCLC). Two hundred forty-one patients were evaluable for survival and 207 for response. We obtained a 25% objective response rate in the standard-dose arm and 29% in the high-dose arm; this difference was not statistically significant. There was no significant improvement in the overall survival or survival of responders with the high-dose regimen. However, toxicity (mainly myelosuppression) was significantly increased in the patients receiving the higher dose of cisplatin. An analysis of prognostic factors showed that disease progression, loss of body weight, performance status, and prior therapy were predictive parameters of survival.

Actuarial Analysis↗
PubMed1983

[Pneumopathy caused by nitrofurantoin].

Two cases of nitrofurantoin induced acute pneumopathy are reported. The characteristics of the pulmonary reactions to this drug are described, and currently accepted pathogenic mechanisms, and diagnostic and therapeutic means discussed.

Acute Disease↗
PubMedDate not supplied

Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.

A combination of cisplatin (60 mg/m2 on Day 1), etoposide (120 mg/m2 on Days 3, 5, and 7), and vindesine (1.5 mg/m2 on Days 1 and 7), repeated every 3 weeks, was administered to 73 patients with non-small cell bronchogenic carcinoma. After two full courses, the results could be evaluated in 62 patients, 25 (40.3%) of whom responded (five complete responses, 20 partial responses). The median survival for the responding patients (12 months) was significantly superior (P = 0.02) to that of the nonresponding patients. There were three early toxic deaths from sepsis associated with granulocytopenia, and seven patients presented peripheral neuropathy. Although active in non-small cell bronchogenic carcinoma, the combination of cisplatin, etoposide, and vindesine does not appear to be superior to cisplatin-etoposide or cisplatin-vindesine when our previous experience and the results reported from other institutions are considered.

Adult↗